While only recently identified as a major health concern, obesity levels have been growing steadily and the condition threatens to rank among the biggest causes of premature death in both the industrialised and emerging economies. With only three products approved worldwide for long-term treatment, and growing unmet clinical need, the treatment of obesity could present a major opportunity area for pharma companies.
Key areas addressed: -Sales forecasts for major launched products -Obesity prevalence and trends -Detailed appraisal of 20 therapies in research -Estimation of launch -Emerging trends and developments
-Focus on leading strategies -Beta3 adrenergic receptor modulators -Cannabinoid receptor modulators -Digestive inhibitors/lipid metabolism modulators -Histaminergic system modulators -Hormone analogues -Monoamine reuptake inhibitors/5-HT receptor modulators -Neuropeptide receptor modulators -Combination therapies.
